Evidence map›Paper›PMID 42353175›Full record

ArticleInternational journal of molecular sciences2026

Novel Experimental Therapeutic Approaches in Glioma-New Hydrazide-Hydrazones as Chemical Agents Sensitizing Glioblastoma Cell Line to Radiotherapy.

Dorota Natorska-Chomicka, Monika Gawrońska-Grzywacz, Paweł Patrejko, Mariola Herbet, Iwona Piątkowska-Chmiel, Magdalena Iwan, Jarosław Dudka, Łukasz Popiołek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dorota Natorska-ChomickaChair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Str., 20-090 Lublin, Poland.
Monika Gawrońska-GrzywaczChair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Str., 20-090 Lublin, Poland.ORCID 0000-0003-0236-2825
Paweł PatrejkoChair and Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki Str., 20-093 Lublin, Poland.
Mariola HerbetChair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Str., 20-090 Lublin, Poland.
Iwona Piątkowska-ChmielChair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Str., 20-090 Lublin, Poland.
Magdalena IwanChair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Str., 20-090 Lublin, Poland.
Jarosław DudkaChair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Str., 20-090 Lublin, Poland.
Łukasz PopiołekChair and Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki Str., 20-093 Lublin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are highly aggressive tumors of the nervous system and remain difficult to treat with currently available therapeutic approaches. Due to their poor prognosis and resistance to standard treatments, there is a growing need for novel strategies, including therapies based on the combined use of radiotherapy and chemotherapy. The aim of this study was to evaluate the potential of newly synthesized hydrazide-hydrazones to sensitize glioblastoma tumor cells to X-ray irradiation. Two novel hydrazide-hydrazones of 5-bromo-2-iodobenzoic acid (

Indexed as

GlioblastomaHydrazinesHydrazonesRadiation-Sensitizing AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalHumansHydrazinesHydrazonesRadiation-Sensitizing Agentsantitumor activitybioactivityglioblastomahydrazide–hydrazone

Identifiers

PMID42353175
PMCPMC13299348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.